PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33545678-2	2021	Recent drug repurposing efforts in multiple solid and hematologic malignancies have demonstrated that eIF4E and EZH2 are both pharmacologically inhibited by the FDA-approved antiviral drug ribavirin.	Ribavirin	189-198	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	112-116	
30454696-8	2018	In addition to eIF4E, ribavirin also modulated phosphorylation of Erk and expression of EZH2 and Snail without affecting Akt and mTOR.	Ribavirin	22-31	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	88-92	
29487714-5	2018	We provide evidence that ribavirin has a significant impact on AT/RT cell growth and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E and/or EZH2 pathways.	Ribavirin	25-34	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	180-184	
27941882-6	2017	Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways.	Ribavirin	21-30	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	167-171	
25738706-1	2015	The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5"-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2).	Ribavirin	53-62	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	196-200	
25738706-5	2015	Ribavirin decreased EZH2 expression, inhibited histone methyltransferase activity and decreased H3K27 trimethylation.	Ribavirin	0-9	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	20-24	
25738706-6	2015	Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin.	Ribavirin	0-9	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	106-110	
25738706-6	2015	Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin.	Ribavirin	292-301	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	106-110	
33545678-10	2021	CONCLUSIONS: The authors demonstrate that ribavirin, a clinically used drug known to inhibit eIF4E and EZH2, has significant antitumor effects in multiple preclinical models of medulloblastoma, including an aggressive group 3 animal model.	Ribavirin	42-51	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	103-107	
31322273-1	2019	Ribavirin exhibits inhibitory effects on the epigenetic enzyme enhancer of zeste homolog 2 (EZH2), which participates in lymphomagenesis.	Ribavirin	0-9	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	63-90	
32606016-7	2020	Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment.	Ribavirin	137-146	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	14-18	
32606016-10	2020	Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium.	Ribavirin	39-48	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	58-62	
31322273-1	2019	Ribavirin exhibits inhibitory effects on the epigenetic enzyme enhancer of zeste homolog 2 (EZH2), which participates in lymphomagenesis.	Ribavirin	0-9	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	92-96